Letters

May 31, 2013 | Letter
Excerpt: The committee’s Subcommittee on Energy and Power has previously conducted oversight relating to the potential impacts of EPA regulations on power plants throughout the United States, including the impact of rules implementing EPA’s regional haze program. We have been concerned about the impacts of EPA’s suite of power sector rules on access to affordable and reliable electricity, and on jobs and the economy.
May 29, 2013 | Letter
Except: Prescription drug counterfeiters have placed our nation's patients at risk; their criminal actions take advantage of the current patchwork of state laws that could allow venue‐shopping for the best locale in which to expose patients to unsafe and counterfeit prescription drugs.
May 23, 2013 | Letter
Excerpt: What is the status of DOC-IG investigative performance? Has it been improving or declining? Has it been affected by controversies and disputes between some current or former DOC law enforcement agents and the DOC-IG management? Has performance been affected by certain personnel practices?; To read the letter, click here.
May 23, 2013 | Letter
Excerpt: It is our understanding that the NRC has a track record of producing cost estimates for its requirements on nuclear power reactors that can be egregiously off target from the actual costs of implementing the requirements. To read the letter, click here. 
May 15, 2013 | Letter
To read EPA's May 15, 2013, response, click here.
May 13, 2013 | Letter
Exceprt: Since the week of February 18, 2013, through the last available listing in April 2013, the FDA's Public Calendar has listed Dr. Brenner-Gati as the Acting Deputy Commissioner for Medical Products and Tobacco with no significant meetings. However, the FDA posted on its website the FDA organizational chart approved and signed on March 4, 2013, by the FDA Reorganization Coordinator listing the position of Deputy Commissioner for Medical Products as vacant. 

Pages